Wang et al. showed that RBM4 shifts splicing of Bcl-x to suppress cancer progression by controlling the balance between pro- and anti-apoptotic pathways, and RBM4 counteracts SRSF1 to inhibit tumor progression by mediating the activation of the mTORC1 pathway21. Here, BCL2L1 is linked to neoplasm.